W
Walter Berger
Researcher at Medical University of Vienna
Publications - 396
Citations - 16667
Walter Berger is an academic researcher from Medical University of Vienna. The author has contributed to research in topics: Cancer & Cell culture. The author has an hindex of 63, co-authored 359 publications receiving 14045 citations. Previous affiliations of Walter Berger include University of Vienna & Université libre de Bruxelles.
Papers
More filters
Journal ArticleDOI
Development of a cobalt(III)-based ponatinib prodrug system
Marlene Mathuber,Michael Gutmann,Mery La Franca,Mery La Franca,Petra Vician,Anna Laemmerer,Patrick Moser,Bernhard K. Keppler,Bernhard K. Keppler,Walter Berger,Christian R. Kowol,Christian R. Kowol +11 more
TL;DR: Hypoxia-activatable prodrugs of the clinically approved tyrosine kinase inhibitor ponatinib are presented for the first time and a correlation of the in vivo activity with their reduction potential is presented.
Landomycins as glutathione-depleting agents and natural fluorescent probes for cellular Michael adduct-dependent quinone metabolism
Alessio Terenzi,Mery La Franca,Sushilla van Schoonhoven,R. R. Panchuk,Álvaro Martínez,Petra Heffeter,Redding Gober,Christine Pirker,Petra Vician,Christian R. Kowol,Christian R. Kowol,Rostyslav Stoika,Luca Salassa,Luca Salassa,Jürgen Rohr,Walter Berger +15 more
TL;DR: In this article, the authors reported that landomycins spontaneously form Michael adducts with biothiols, including reduced cysteine and glutathione, both cell-free or intracellularly involving the benz[a]anthraquinone moiety of landomycinone.
Journal ArticleDOI
Thermodynamic Genome-Scale Metabolic Modeling of Metallodrug Resistance in Colorectal Cancer
Helena A. Herrmann,Mate Rusz,Dina Baier,Michael A. Jakupec,Michael A. Jakupec,Bernhard K. Keppler,Bernhard K. Keppler,Walter Berger,Gunda Koellensperger,Jürgen Zanghellini +9 more
TL;DR: In this paper, the authors constrain four instances of a thermodynamic genome-scale metabolic model of the HCT116 colorectal carcinoma cell line to compare the metabolic flux profiles of cells that are either sensitive or resistant to ruthenium- or platinum-based treatments with BOLD-100/KP1339 and oxaliplatin, respectively.
Patent
Monomaleimide-functionalized platinum compounds for cancer therapy
Christian R. Kowol,Petra Heffeter,Walter Berger,Bernhard K. Keppler,Josef Mayr,Verena Pichler +5 more
TL;DR: In this paper, the present invention relates to novel monomaleimide-functionalized platinum compounds of formula (I), including in particular novel monomialimide functionalized oxaliplatin and carboplatin derivatives, as well as their use as medicaments.
Journal ArticleDOI
Non-viral gene delivery of the oncotoxic protein NS1 for treatment of hepatocellular carcinoma
Dominik Witzigmann,Philip Grossen,Cristina Quintavalle,Manuela Lanzafame,Susanne H. Schenk,Xue-Ting Tran,Bernhard Englinger,Patrick Hauswirth,David Grünig,Sushilla van Schoonhoven,Stephan Krähenbühl,Luigi Terracciano,Walter Berger,Salvatore Piscuoglio,Luca Quagliata,Jean Rommelaere,Jürg P. F. Nüesch,Jörg Huwyler +17 more
TL;DR: In this paper, the authors exploit a non-viral gene therapy enabling the expression of the parvirus-derived oncotoxic protein NS1 in HCC, which interacts with different cellular kinases mediating multimodal host-cell death.